Holen Sie sich die Stockscreener-App
140.50
7.00%
9.0017
Schlusskurs vom Vortag:
$131.50
Offen:
$132.59
24-Stunden-Volumen:
848.68K
Relative Volume:
1.24
Marktkapitalisierung:
$9.01B
Einnahmen:
$74.06M
Nettoeinkommen (Verlust:
$-114.71M
KGV:
-77.89
EPS:
-1.8039
Netto-Cashflow:
$-117.90M
1W Leistung:
+14.78%
1M Leistung:
+44.49%
6M Leistung:
+70.88%
1J Leistung:
+182.13%
1-Tages-Spanne:
$130.69
$140.97
1-Wochen-Bereich:
$122.48
$140.56
52-Wochen-Spanne:
$49.38
$140.56
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
140.08 | 8.46B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com
Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView
Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD - Investing.com
Protagonist Therapeutics updates its pipeline. PTGX focuses on peptide drug development - AD HOC NEWS
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock - Yahoo Finance
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics awards new hires stock options and RSUs - Stock Titan
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
PTGXProtagonist Therapeutics Inc Latest SEC Filings - Finviz
Why (PTGX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 4 Protagonist Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTGX) - TradingView
Protagonist Therapeutics director Waddill sells $1.06m in stock By Investing.com - Investing.com Australia
Protagonist Therapeutics director Waddill sells $1.06m in stock - Investing.com
Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan - Stock Titan
Protagonist Therapeutics stock hits all-time high at 124.97 USD By Investing.com - Investing.com South Africa
PTGX Forecast — Price Target — Prediction for 2027 - TradingView
Protagonist Therapeutics stock hits all-time high at 124.97 USD - Investing.com
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Why Is Silence Therapeutics Stock Soaring Wednesday?Silence Therapeutics (NASDAQ:SLN) - Benzinga
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest - Sahm
Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com - Investing.com India
PTGX (NASDAQ) Form 144: Director-linked 9,000-share sales and option exercise - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Protagonist Therapeutics (PTGX) Edges Higher, Testing Key Resistance Zone Near $118.5Covered Call Trade - Město Břeclav
Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com - Investing.com India
Protagonist Therapeutics Adopts 2026 Equity Incentive Plan Following Shareholder Approval - Minichart
Protagonist Therapeutics (PTGX) OKs 2026 equity plan and re-elects directors at annual meeting - Stock Titan
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Protagonist Therapeutics stock hits all-time high at 113.75 USD - Investing.com
Protagonist Therapeutics Inc (PTGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protagonist Therapeutics Inc (PTGX) Institutional Confidence - TradingKey
Protagonist Therapeutics Inc - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PTGX: All proposals, including director elections and equity plan, were approved at the AGM - TradingView
Understanding Momentum Shifts in (PTGX) - Stock Traders Daily
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 23 '26 |
Sale |
117.94 |
9,000 |
1,061,460 |
7,825 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):